BEAMBeam Therapeutics Inc.
Price
+5.7%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth steady, the market against it.
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Beam Therapeutics Inc. (BEAM) reported revenue of $490K in Q2 2026 (quarter ended Jun 30, 2026), down 94% from the same quarter a year earlier. That came with net loss of $123M. For the full year FY2025, revenue was $140M (+120% year on year) and net income −$80M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)Earnings release · press release
- May 7, 2026Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
- Mar 5, 2026Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kobe University On March 2, 2026 (the “Termination Date”), Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio …Material agreement terminated · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.